Numelvi vs. Apoquel vs. Cytopoint: How the Newest Dog Allergy Tablet Compares

For years, the two names in dog itch control were Apoquel, a daily tablet, and Cytopoint, an injection. In 2026, Merck Animal Health added a third name many owners are now hearing at the vet: Numelvi. It's a tablet like Apoquel, but newer, more selective in how it works, and approved for younger dogs. Here's how the three compare, what the evidence does and doesn't show yet, and where each one falls short.

Two Ways to Stop the Itch

When an allergic dog meets pollen, dust mites or another trigger, the immune system releases messengers called cytokines. Several of them, including interleukin-31 (IL-31), tell the nerves in the skin to itch. The three drugs interrupt that process in two different ways.

Numelvi and Apoquel are JAK inhibitors. Cytokines pass their message into cells through enzymes called Janus kinases (JAKs). Blocking JAK1 in particular quiets several itch and inflammation signals at once. Merck reports that Numelvi is at least ten times more selective for JAK1 than for the other JAK enzymes in lab testing, with the aim of leaving other immune pathways more alone.

Cytopoint is an antibody. Instead of blocking the cell's machinery, it mops up IL-31 itself before it reaches the nerves. It's more targeted, since it acts on one messenger, and it's given as an injection rather than a pill. Befrena, from Elanco, works the same way; see Befrena vs. Cytopoint.

At a Glance

Numelvi vs. Apoquel

These two are the closest comparison, since they're the same kind of drug. The practical differences:

• Dosing. Numelvi is given once a day, with food, from the first dose. Apoquel starts at twice a day for up to two weeks, then drops to once a day. For owners who struggle with the twice-daily start, that's a real difference.
• Age. Numelvi is labeled for dogs six months and older, Apoquel for dogs 12 months and older. If you have a young dog with early, severe itch, that matters.
• Selectivity. Numelvi is designed to be more selective for JAK1. Whether that translates into fewer side effects in everyday use is something only time and more data will show.
• Track record. Apoquel has been in everyday use since 2013, so vets have more than a decade of experience with it. Numelvi's label notes that its field study ran 28 days, so long-term experience is still building.

Merck's US approval was based on a placebo-controlled field study, which is the standard path for a new drug; the details are in the FDA's Freedom of Information summary. We're not aware of a published study comparing Numelvi directly with Apoquel. The only head-to-head trial between two JAK inhibitors so far compared Zenrelia with Apoquel, which we cover in Zenrelia vs. Apoquel vs. Cytopoint.

Numelvi vs. Cytopoint

This is less a contest than a choice of format. Numelvi is a pill you give at home every day. Cytopoint is a shot your vet gives every month or two. Some owners find a daily tablet easy; others would rather not think about it between visits. Cytopoint also has no age limit and acts on just one itch messenger, which some vets prefer for very young dogs or dogs with other health issues. Numelvi acts on several signals at once, which can help when itch and inflammation are both part of the picture.

Numelvi's label says its safe use hasn't been evaluated alongside steroids, cyclosporine or other systemic immunosuppressants. If your dog is already on one of those, or your vet is thinking of combining treatments, that's a conversation to have before starting.

Safety Notes for JAK Inhibitors

Because JAK inhibitors dial down parts of the immune response, their labels share some common cautions. They're generally not used in dogs with serious active infections, and vets keep an eye out for skin and ear infections, demodex mites and lumps while a dog is on them. Like other drugs in its class, Numelvi isn't intended for breeding, pregnant or lactating dogs; ask your vet if that applies to yours. Your vet will usually want a baseline exam, and often bloodwork, before starting and at intervals afterward.

What None of Them Do

Numelvi, Apoquel and Cytopoint are all itch controllers. They work while your dog is taking them, and when they stop, the itch usually returns, because the immune system is still reacting to the same allergens. That's why many dogs stay on one of them for years.

Allergen immunotherapy is the treatment aimed at the allergy itself. It uses small, gradually increasing amounts of the specific allergens your dog tested positive for, so the immune system learns to tolerate them. The ICADA treatment guidelines recognize it as the option that can change the course of atopic dermatitis. It takes months to build, so it's commonly started while a dog stays on an itch controller, which is then reduced as the immunotherapy takes hold.

Choosing With Your Vet

If your dog is doing well on Apoquel or Cytopoint, there's no need to switch just because something newer exists. Numelvi is worth asking about if your dog is under a year old, if the twice-daily Apoquel start has been a struggle, or if your current medication isn't controlling the itch well. Whichever you choose, ask the bigger question too: does your dog need itch medication indefinitely, or is it time for allergy testing and a long-term plan? For every option side by side, see our full guide to alternatives to Apoquel and Cytopoint.

Common Questions

Is Numelvi better than Apoquel? There's no head-to-head study yet, so nobody can say that. Numelvi is more selective for JAK1 in lab testing, is given once daily from the start, and is labeled from six months of age rather than twelve. Apoquel has more than a decade of real-world use behind it. Which suits your dog is a decision to make with your vet.

Can Numelvi be given with Cytopoint? The Numelvi label says its safe use hasn't been evaluated with steroids, cyclosporine or other systemic immunosuppressants. It doesn't specifically address Cytopoint. Vets sometimes combine a daily tablet with an anti-itch injection for hard-to-control dogs, but that's a case-by-case call for your vet.

Is Numelvi a steroid? No. Numelvi (atinvicitinib) is a Janus kinase (JAK) inhibitor, the same drug class as Apoquel and Zenrelia. It works by blocking the signaling of specific itch and inflammation messengers rather than suppressing the immune system broadly the way steroids do.

What age can a dog start Numelvi? Numelvi is labeled for dogs six months and older. Apoquel and Zenrelia are labeled for dogs 12 months and older. Cytopoint and Befrena injections can be used in dogs of any age.

Is there a cheaper alternative to Numelvi? Numelvi is still new and has no generic. Prices for Numelvi, Apoquel and Zenrelia all depend on your dog's weight and your clinic, so ask your vet to quote the monthly cost of each for your dog. Over the long term, allergen immunotherapy may reduce how much itch medication your dog needs.

Can cats take Numelvi? No. Numelvi is labeled for dogs only. For cats, vets commonly use steroids, cyclosporine or allergen immunotherapy. Allibre is formulated for both dogs and cats.